Global Novel Coronavirus (COVID-19) Vaccine Market

Market Size in USD Billion

CAGR : 17.60%

USD 1.14

2025

USD 4.17

2033

Forecast Period	2025 - 2033
Market Size (Base Year)	USD 1.14 Billion
Market Size (Forecast)	USD 4.17 Billion
CAGR	17.60%
Major Market Players	Data provided in full report

Extent Research has published another latest report on global Novel Coronavirus (COVID-19) Vaccine Market for providing a better understanding of the overall market analytics and valuation under a single roof. The report scrutinizes the market dynamics through historical growth trajectory, present conditions, and future growth prospects. It can thus be observed that the report provides each and every detail right from the past up to the future prospects of the market for the extensive knowledge of the readers, especially investors. The information comprehended in the report help form a strong base for the future projections during the forecast period. The report also profiles the opportunities & challenges and drivers & restraints that have a major impact on the growth rate of the Novel Coronavirus (COVID-19) Vaccine market.

Data provided by Extent Research. Source: https://www.extentresearch.com/novel-coronavirus-covid-19-vaccine-market

Segmentation Study:

The various segments of the global Novel Coronavirus (COVID-19) Vaccine industry offers more insight to the market from the regional and global point of view. The study of the segments helps understand the markets position and financial outcomes. The Novel Coronavirus (COVID-19) Vaccine market is segmented into by Product type DNA, RNA, Others, , by Application Mild Symptom Patient, Critically Ill Patient, .

Competitive Landscape:

The global Novel Coronavirus (COVID-19) Vaccine market size could be well grasped through the share, revenue, and size numerical data presented in the report. The in-depth industrial analysis assists in gaining better understanding of the changing competitive dynamics. Additionally, the market strategies including mergers & acquisition, agreement, collaborations, and joint ventures provide readers comprehensive overview of the Novel Coronavirus (COVID-19) Vaccine industry from both the regional and global perspective. Some of the key players in the Novel Coronavirus (COVID-19) Vaccine market include Inovio Pharmaceuticals, Takis Biotech (Evvivax), Zydus Cadila, Codagenix, Inc., GeoVax, Inc., Bravovax, Janssen Pharmaceutical Companies, Altimmune, Vaxart, CanSino Biologics, ExpreS2ion Biotechnologies ApS, Clover Biopharmaceuticals, GSK, Vaxil Bio Ltd., Generex, Novavax, Inc., Sanofi Pasteur, Baylor, iBio, Inc., Moderna, Inc., Curevac, ImmunoPrecise, .

Regional Analysis:

Geographical study of the global Novel Coronavirus (COVID-19) Vaccine market elaborate more about the market’s economic growth and regional market attraction. The report shows the regions North America, Europe, Asia Pacific, Latin America, Middle East & Africa to be the major market preferences owing to the consumer preferences, economic gains, supply & demand analysis, and supplementary factors.

What does the report offer?

Detailed market analytics and market valuation
Market share of the key market players
Market forecast based on the historical and current data
Industrial strategies, opportunities, and challenges for the new entrants
Market segments for better assessment of market growth on regional and global level
Growth mapped by the competitive landscape and geographical distribution

Report Scope and Market Segmentation

ATTRIBUTES	Global Novel Coronavirus (COVID-19) Vaccine Market KEY MARKET INSIGHTS
Segments Covered	By Product Type: All Products Type Includes By Application: All Application Type Includes By End User: All End User Type Includes By Distribution Channel: All Distribution Channel Includes
Countries Covered	North America U.S., Canada, Mexico Europe Germany, United Kingdom, France, Italy, Spain, Nordic Countries, Benelux Union, Rest of Europe Asia-Pacific China, India, Japan, New Zealand, South Korea, Australia, Southeast Asia, Rest of Asia Pacific Latin America Brazil, Argentina, Rest of Latin America Middle East & Africa Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa
Key Market Players	Leading Tier 1 Corporations Prominent Regional Manufacturers Emerging Market Disruptors Technology Integrators & Suppliers *Complete vendor layout of 15+ major players provided in the final report.
Market Opportunities	Market Size and Growth: Quantifying the total addressable market (TAM) and projected growth rates to assess financial viability. Customer Segmentation: Identifying target audience behaviors, pain points, and specific unfulfilled demands. Competitive Landscape: Analyzing existing competitors' strengths, weaknesses, and market share to pinpoint gaps and opportunities. Industry Trends: Mapping technological, regulatory, and economic shifts that create favorable conditions for market entry. Risk Assessment: Evaluating barriers to entry and operational challenges alongside strategic roadmaps for mitigation.
Value Added Data Infosets	In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by our expert team also include in-depth expert analysis, geographically represented company-wise production and capacity, network layouts of distributors and partners, detailed and updated price trend analysis and deficit analysis of supply chain and demand.

Meet the Team

Julie

Author

Julie Jayne is a distinguished multidisciplinary strategist and the Head of Research at Extent Research, where she leverages over a decade of comprehensive experience in the global market intelligence industry. Backed by a robust academic foundation that includes a B.Sc. and an MBA, she perfectly...

Priya M

Reviewed By

With over 14 years of dedicated professional expertise in business-to-business (B2B) intelligence, Priya M stands as a distinguished leader in corporate strategy, revenue growth, and advanced data analysis. Her dynamic career is defined by a relentless focus on mitigating business risks and empowering corporate executives...

Learn more about Priya M

BASIC ATTRIBUTES \| KEY MARKET INSIGHTS
Report Title	Global Novel Coronavirus (COVID-19) Vaccine Market
Base Year	2025
Forecast Period	2025 - 2033
Market Size (Base)	USD 1.14 Billion
Projected Size	USD 4.17 Billion
CAGR	17.60%

                            1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate by Type (2022-2035)
        1.2.2 DNA
        1.2.3 RNA
        1.2.4 Others
    1.3 Market by Application
        1.3.1 Global Novel Coronavirus (COVID-19) Vaccine Market Share by Application (2022-2035)
        1.3.2 Mild Symptom Patient
        1.3.3 Critically Ill Patient
    1.4 Study Objectives
    1.5 Years Considered
2 Executive Summary
    2.1 Global Novel Coronavirus (COVID-19) Vaccine Market Size
    2.2 Novel Coronavirus (COVID-19) Vaccine Market Size by Regions
        2.2.1 Novel Coronavirus (COVID-19) Vaccine Growth Rate by Regions (2022-2035)
        2.2.2 Novel Coronavirus (COVID-19) Vaccine Market Share by Regions (2022-2035)
    2.3 Industry Trends
        2.3.1 Market Top Trends
        2.3.2 Market Use Cases
3 Key Players
    3.1 Novel Coronavirus (COVID-19) Vaccine Revenue by Players (2022 & 2035)
    3.2 Novel Coronavirus (COVID-19) Vaccine Key Players Headquarters and Area Served
    3.3 Key Players Novel Coronavirus (COVID-19) Vaccine Product/Solution/Service
    3.4 Date of Enter into Novel Coronavirus (COVID-19) Vaccine Market
    3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown by Type and by Application
    4.1 Global Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2022-2035)
    4.2 Global Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2022-2035)
5 North America
    5.1 North America Novel Coronavirus (COVID-19) Vaccine Market Forecast (2022-2035)
    5.2 Novel Coronavirus (COVID-19) Vaccine Key Players in North America
    5.3 North America Novel Coronavirus (COVID-19) Vaccine Market Size by Type
    5.4 North America Novel Coronavirus (COVID-19) Vaccine Market Size by Application
6 Europe
    6.1 Europe Novel Coronavirus (COVID-19) Vaccine Market Forecast (2022-2035)
    6.2 Novel Coronavirus (COVID-19) Vaccine Key Players in Europe
    6.3 Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Type
    6.4 Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Application
7 Asia-Pacific
    7.1 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Forecast (2022-2035)
    7.2 Novel Coronavirus (COVID-19) Vaccine Key Players in Asia-Pacific
    7.3 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Size by Type
    7.4 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Size by Application
8 Rest of World
    8.1 Latin America
        8.1.1 Latin America Novel Coronavirus (COVID-19) Vaccine Market Analysis
        8.1.2 Key Players in Latin America
    8.2 Middle East & Africa
        8.2.1 Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Market Analysis
        8.2.2 Key Players in Middle East & Africa
9 International Player Profiles
    9.1 Inovio Pharmaceuticals
        9.1.1 Inovio Pharmaceuticals Company Details
        9.1.2 Inovio Pharmaceuticals Description and Business Overview
        9.1.3 Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Introduction
        9.1.4 Inovio Pharmaceuticals Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2035)
        9.1.5 Inovio Pharmaceuticals Recent Development
    9.2 Takis Biotech (Evvivax)
        9.2.1 Takis Biotech (Evvivax) Company Details
        9.2.2 Takis Biotech (Evvivax) Description and Business Overview
        9.2.3 Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Introduction
        9.2.4 Takis Biotech (Evvivax) Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2035)
        9.2.5 Takis Biotech (Evvivax) Recent Development
    9.3 Zydus Cadila
        9.3.1 Zydus Cadila Company Details
        9.3.2 Zydus Cadila Description and Business Overview
        9.3.3 Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Introduction
        9.3.4 Zydus Cadila Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2035)
        9.3.5 Zydus Cadila Recent Development
    9.4 Codagenix, Inc.
        9.4.1 Codagenix, Inc. Company Details
        9.4.2 Codagenix, Inc. Description and Business Overview
        9.4.3 Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction
        9.4.4 Codagenix, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2035)
        9.4.5 Codagenix, Inc. Recent Development
    9.5 GeoVax, Inc.
        9.5.1 GeoVax, Inc. Company Details
        9.5.2 GeoVax, Inc. Description and Business Overview
        9.5.3 GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction
        9.5.4 GeoVax, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2035)
        9.5.5 GeoVax, Inc. Recent Development
    9.6 Bravovax
        9.6.1 Bravovax Company Details
        9.6.2 Bravovax Description and Business Overview
        9.6.3 Bravovax Novel Coronavirus (COVID-19) Vaccine Introduction
        9.6.4 Bravovax Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2035)
        9.6.5 Bravovax Recent Development
    9.7 Janssen Pharmaceutical Companies
        9.7.1 Janssen Pharmaceutical Companies Company Details
        9.7.2 Janssen Pharmaceutical Companies Description and Business Overview
        9.7.3 Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Introduction
        9.7.4 Janssen Pharmaceutical Companies Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2035)
        9.7.5 Janssen Pharmaceutical Companies Recent Development
    9.8 Altimmune
        9.8.1 Altimmune Company Details
        9.8.2 Altimmune Description and Business Overview
        9.8.3 Altimmune Novel Coronavirus (COVID-19) Vaccine Introduction
        9.8.4 Altimmune Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2035)
        9.8.5 Altimmune Recent Development
    9.9 Vaxart
        9.9.1 Vaxart Company Details
        9.9.2 Vaxart Description and Business Overview
        9.9.3 Vaxart Novel Coronavirus (COVID-19) Vaccine Introduction
        9.9.4 Vaxart Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2035)
        9.9.5 Vaxart Recent Development
    9.10 CanSino Biologics
        9.10.1 CanSino Biologics Company Details
        9.10.2 CanSino Biologics Description and Business Overview
        9.10.3 CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Introduction
        9.10.4 CanSino Biologics Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2035)
        9.10.5 CanSino Biologics Recent Development
    9.11 ExpreS2ion Biotechnologies ApS
        9.11.1 ExpreS2ion Biotechnologies ApS Company Details
        9.11.2 ExpreS2ion Biotechnologies ApS Description and Business Overview
        9.11.3 ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Introduction
        9.11.4 ExpreS2ion Biotechnologies ApS Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2035)
        9.11.5 ExpreS2ion Biotechnologies ApS Recent Development
    9.12 Clover Biopharmaceuticals
        9.12.1 Clover Biopharmaceuticals Company Details
        9.12.2 Clover Biopharmaceuticals Description and Business Overview
        9.12.3 Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Introduction
        9.12.4 Clover Biopharmaceuticals Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2035)
        9.12.5 Clover Biopharmaceuticals Recent Development
    9.13 GSK
        9.13.1 GSK Company Details
        9.13.2 GSK Description and Business Overview
        9.13.3 GSK Novel Coronavirus (COVID-19) Vaccine Introduction
        9.13.4 GSK Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2035)
        9.13.5 GSK Recent Development
    9.14 Vaxil Bio Ltd.
        9.14.1 Vaxil Bio Ltd. Company Details
        9.14.2 Vaxil Bio Ltd. Description and Business Overview
        9.14.3 Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Introduction
        9.14.4 Vaxil Bio Ltd. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2035)
        9.14.5 Vaxil Bio Ltd. Recent Development
    9.15 Generex
        9.15.1 Generex Company Details
        9.15.2 Generex Description and Business Overview
        9.15.3 Generex Novel Coronavirus (COVID-19) Vaccine Introduction
        9.15.4 Generex Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2035)
        9.15.5 Generex Recent Development
    9.16 Novavax, Inc.
        9.16.1  Company Details
        9.16.2 Novavax, Inc. Description and Business Overview
        9.16.3 Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction
        9.16.4 Novavax, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2035)
        9.16.5 Novavax, Inc. Recent Development
    9.17 Sanofi Pasteur
        9.17.1 Sanofi Pasteur Company Details
        9.17.2 Sanofi Pasteur Description and Business Overview
        9.17.3 Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Introduction
        9.17.4 Sanofi Pasteur Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2035)
        9.17.5 Sanofi Pasteur Recent Development
    9.18 Baylor
        9.18.1 Baylor Company Details
        9.18.2 Baylor Description and Business Overview
        9.18.3 Baylor Novel Coronavirus (COVID-19) Vaccine Introduction
        9.18.4 Baylor Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2035)
        9.18.5 Baylor Recent Development
    9.19 iBio, Inc.
        9.19.1 iBio, Inc. Company Details
        9.19.2 iBio, Inc. Description and Business Overview
        9.19.3 iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction
        9.19.4 iBio, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2035)
        9.19.5 iBio, Inc. Recent Development
    9.20 Moderna, Inc.
        9.20.1 Moderna, Inc. Company Details
        9.20.2 Moderna, Inc. Description and Business Overview
        9.20.3 Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction
        9.20.4 Moderna, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2035)
        9.20.5 Moderna, Inc. Recent Development
    9.21 Curevac
        9.21.1 Curevac Company Details
        9.21.2 Curevac Description and Business Overview
        9.21.3 Curevac Novel Coronavirus (COVID-19) Vaccine Introduction
        9.21.4 Curevac Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2035)
        9.21.5 Curevac Recent Development
    9.22 ImmunoPrecise
        9.22.1 ImmunoPrecise Company Details
        9.22.2 ImmunoPrecise Description and Business Overview
        9.22.3 ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Introduction
        9.22.4 ImmunoPrecise Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2035)
        9.22.5 ImmunoPrecise Recent Development
10 Market Dynamics
    10.1 Industry Trends
    10.2 Market Drives
    10.3 Market Challenges
    10.4 Market Restraints
11 Key Findings in This Report
12 Appendix
    12.1 Research Methodology
        12.1.1 Methodology/Research Approach
        12.1.2 Data Source
    12.2 Disclaimer
    12.3 Author Details                        

Research Methodology

Data collection and base year analysis are done using proprietary data collection modules with large sample sizes. The process includes obtaining market information through extensive secondary sources, paid databases, and verifying data via primary (industry expert) validation.

Our market models include Vendor Positioning Grids, Market Timeline Analysis, Company Market Share Analysis, and Top-Down/Bottom-Up forecasting models. To know more about the research methodology, drop an inquiry to speak to our industry experts.

Speak to Analyst

Global Novel Coronavirus (COVID-19) Vaccine Market